The FDA turned down a Johnson & Johnson application for a new experimental leukemia drug. The drug was called tipifarnib.
Tipifarnib is an oral medication studied to treat acute
myeloid leukemia in elderly patients who are not candidates for
standard chemotherapy.
Source: Reuters at Yahoo